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Cardiac-related death has been reported following strenuous exercise, and biochemical markers predicting adverse outcomes would be useful. Despite the fact the myeloperoxidase (MPO) release may precede myocardial injury and identify at-risk patients earlier than traditional markers, information on the effects of marathon running on MPO levels is lacking. We measured MPO in conjunction with the creatine kinase MB fraction (CK-MB), myoglobin, troponin T (TnT), and N-terminal B-type natriuretic peptide (NT-proBNP) in 24 athletes before and after a marathon race. Of the 24 athletes, 22 (92%) had an increased MPO level, and the mean MPO level increased from 281.44 pmol/L to 785.21 pmol/L (P < .0001). Results for 14 (58%) of the athletes reached or exceeded the manufacturer's recommended clinical threshold. The increases in CK-MB, myoglobin, TnT, and NT-proBNP also reached statistical significance. Although the elevation in MPO most likely represents a systemic inflammatory response, the concurrent elevations in TnT and NTproBNP suggest that myocardial injury cannot be excluded.
Physical activity provides many benefits to cardiovascular health, including lowering blood pressure, improving lipid profiles, modulating insulin resistance, and decreasing overall mortality. 1, 2 However, the occurrence of cardiac death or other adverse events has also been reported after vigorous exercise. [3] [4] [5] [6] [7] [8] [9] Although the incidence of cardiac events after strenuous exercise is extremely low, understanding the pathophysiology and identifying athletes at risk could prevent adverse outcomes in unsuspecting individuals.
Previous studies have demonstrated elevations in various biochemical markers following strenuous exercise such as marathon running. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Most changes can be attributed to skeletal muscle injury (eg, creatine kinase MB fraction [CK-MB] and myoglobin level) or inflammation (eg, C-reactive protein level and WBC count). 11, 16, 17 However, the consequences of elevations in cardiospecific markers such as troponin have been debated. 17, 18 Some studies have shown no elevations in troponin, 13, 19 whereas others reported increases below, at, or above the clinical threshold for myocardial necrosis in some subjects following marathon running. 10, [14] [15] [16] Studies have differed in terms of age and training status of the subjects and the manufacturers of the assays used for individual markers. In 1 report, sestamibi imaging 16 and echocardiography 20 performed in parallel with troponin testing illustrated no evidence of microinfarction or change in cardiac function after strenuous exercise. Troponin is released early (ie, during or immediately after a 4-hour marathon) and normalizes within 24 to 48 hours. 10, 16 This pattern may suggest that troponin is released from the free cytoplasmic pool reflecting myocardial stunning, oxidative stress, or transient ischemia but not irreversible myocardial injury. 14, 15 Small elevations of troponin may also signify minor myocardial damage, but the potential cardiac consequences in at-risk athletes are still unknown. 7 Myeloperoxidase (MPO) is a hemoprotein expressed in neutrophils that has recently been implicated in the pathogenesis of cardiovascular disease and may be elevated in patients with acute coronary syndromes. [21] [22] [23] [24] [25] [26] Several studies have investigated the diagnostic and prognostic role of MPO in coronary artery disease. 22, 27 Release of MPO may precede myocardial injury and identify patients earlier who are at risk for cardiac ischemia or thrombosis. 22 In this article, we report MPO levels in conjunction with the levels of other biochemical markers to further elucidate the effects of marathon running on biochemical markers of myocardial injury.
Materials and Methods
Approval for this study was obtained by the institutional Human Research Committee of Massachusetts General Hospital, Boston, and McLean Hospital, Belmont, MA. Twenty-four nonprofessional marathon runners were recruited by open invitation from local running clubs. All athletes provided written consent and completed a comprehensive screening no more than 1 week before the race and no less than 15 minutes after the race. The prerace screening inquired about current and past medical conditions, family history, and use of prescription medications.
Whole blood samples were collected in EDTA and serum separator tubes before and within 30 minutes of completion of the 2005 Boston Marathon. All specimens were processed immediately. None of the specimens showed signs of hemolysis. Aliquots were frozen within 1 hour of collection at -80°C.
MPO, CK-MB, myoglobin, troponin T (TnT), and N-terminal B-type natriuretic peptide (NT-proBNP) were measured before and immediately after the Boston Marathon. MPO, CK-MB, and myoglobin were measured by rapid quantitative immunofluorescence using the Triage instrument system (Biosite Diagnostics, San Diego, CA). These tests were performed by Biosite using a research Triage meter on blinded specimens. The analytic ranges were as follows: MPO, 10-6,500 pmol/L; CK-MB, 0.1-80 ng/mL; and myoglobin, 0.86-500 ng/mL. Diagnostic cut points for MPO, CK-MB, and myoglobin were 500 pmol/L (coefficient of variation [CV], 13%), 4.3 ng/mL (CV, 11%), and 107 ng/mL (CV, 12%), respectively. Levels above the cut point were considered clinically significant and indicate the presence of disease.
TnT and NT-proBNP were measured by electrochemiluminescence on a Roche Elecsys 1010 platform (Roche Diagnostics, Indianapolis, IN). A value of 0.03 ng/mL (0.03 µg/L) provides a 10% CV and was chosen as the upper limit of normal for TnT. 28, 29 A value of more than 0.1 ng/mL (>0.1 µg/L) is considered indicative of myocardial necrosis at the Massachusetts General Hospital. NT-proBNP cut points are age-dependent (<50 years, 0-450 pg/mL; 50-75 years, 0-900 pg/mL; and >75 years, 0-1,500 pg/mL). An age-independent cut point of 300 pg/L (CV, <4%) can be used to rule out acute congestive heart failure. 30 Statistical analysis was performed on Analyse-It (Analyse-It, Leeds, England) using the 2-tailed Student t test. P values less than .05 were considered statistically significant.
Results
All 24 runners completed the 2005 Boston Marathon and provided whole blood specimens before and after the race. The race was run at a temperature of 69°F to 70°F with light north-northwesterly winds at 3 mph. Of the athletes, 19 were men and 5 were women with a mean age of 49.2 years (SD ± 6.4 years). The runners completed the race in an average of 250 minutes (SD ± 33 minutes). None of the athletes experienced adverse events throughout the race, and all runners were deemed in medically stable condition at the conclusion of the marathon.
MPO was measured in all 24 marathon runners before and immediately after the 2005 Boston Marathon ❚Table 1❚. In 22 (92%) of 24, MPO increased with an average percentage change of 222.95 pmol/L ❚Table 2❚. CK-MB, myoglobin, TnT, and NT-proBNP were measured on the same specimens, if available (Table 1) . Data for TnT were previously published in a separate report. 31 CK-MB, myoglobin, and NT-proBNP levels increased in all runners by an average of 655.84%, >936.36%, and 499.39%, respectively ( Table 2 ). The TnT was elevated from premarathon levels in 77% of runners. The average percentage change in TnT was 195.20% (Table 2) .
The mean MPO level increased from 281.44 (SD ± 130.91) to 785.21 (SD ± 465.22) pmol/L (P < .0001) ❚Table 3❚. In 14 runners (58%), the level reached or exceeded the manufacturer's recommended clinical threshold. The elevation in CK-MB from 1.88 (SD ± 0.99) to 11.43 (SD ± 15.89) ng/mL after the race also reached statistical significance (P = .0074). Of the athletes, 79% had a CK-MB level greater than 4.3 ng/mL, which is the cut point used clinically at Massachusetts General Hospital to assess the risk of acute coronary syndrome. Myoglobin increased significantly from 52.53 ± 17.32 to greater than 500 ng/mL (P < .0001), and levels in all runners were above the cut point of 107 ng/mL.
The levels of cardiac-specific markers, TnT and NTproBNP, were increased above prerace levels in most runners. The mean TnT was 0.01 (SD ± 0.0008) ng/mL before the marathon and 0.03 (SD ± 0.02) ng/mL after the marathon (P < .0001) ( (rounding off to 2 decimal places). NT-proBNP increased from 36.57 (SD ± 40.0) to 150.21 (SD ± 102.55) pg/mL (P < .0001). Although no runners showed an increase in NTproBNP of more than 450 pg/mL, all showed an increase in NT-proBNP with an average increase of 499.39%. In addition, 2 runners exceeded the age-independent cut point of 300 pg/mL to rule out congestive heart failure.
Discussion
Previous studies have demonstrated biochemical evidence of cardiac injury or myocardial dysfunction following endurance sports. 10, [14] [15] [16] 18 Our article is the first to describe an elevation in the MPO level in marathon runners in conjunction with other biochemical markers used to assess cardiac function.
Severe strenuous exercise induces a sequence of cellular and humoral changes similar to those characterizing an acute inflammatory response. Proinflammatory cytokines, which recruit and prime neutrophils and monocytes, and anti-inflammatory cytokines, which prevent exercise-induced oxidative stress, are released. [32] [33] [34] It has been reported that an imbalance in prothrombotic and fibrinolytic factors after physical exertion may transiently increase the risk of coronary thrombosis and acute ischemic events. 18 The persistence of procoagulant effects may relate to the occurrence of sudden cardiac death after vigorous exercise, although this occurs at a low prevalence.
MPO is a marker of inflammation and neutrophil activation during strenuous exercise. 35 In addition, it has been implicated in the oxidation of lipids contained in low-density lipoproteins, infiltration of macrophages and neutrophils, formation of unstable coronary plaques, and plaque rupture. [22] [23] [24] [25] [26] Owing to its role in inflammation in the atherosclerotic process, several studies have investigated the role of MPO in monitoring cardiovascular disease. 22, 27 MPO is elevated in patients with coronary artery disease and correlates with angiographically proven coronary atherosclerosis. 27 Patients with elevated MPO levels experience a markedly increased risk of cardiac events despite the fact that their troponin levels may be normal. 22 Furthermore, MPO provides prognostic information beyond that gained from traditional cardiac markers, such as troponin and CK-MB, and may identify patients with unstable plaques before complete microvascular obstruction.
We measured MPO in addition to other biochemical markers to determine the effect of marathon running on these analytes and help elucidate biochemical changes associated with endurance exercise. A statistically significant increase in all markers was found after the marathon race. Skeletal muscle injury and release of myofibrillar enzymes is expected during vigorous exercise. Therefore, the elevation in CK-MB and myoglobin levels most likely reflects acute skeletal muscle injury due to exertional rhabdomyolysis. 17 In contrast, elevations in NT-proBNP may represent an appropriate volume regulatory response of a hemodynamically stressed heart to prolonged exercise. Other studies have illustrated that the increase in BNP is not due to changes in sodium concentration because in these studies, the sodium levels remained normal. 14 Our findings corroborate this conclusion. In a previous study, no parallel increase was found in sodium with NT-proBNP. 31 Alternatively, the elevation in the NT-proBNP level may represent an ischemic burden secondary to extreme exercise. 36 The rise in the TnT level observed in our subjects may reflect transient ischemia, myocardial stunning, or potentially minor myocardial damage, as discussed in earlier reports. 17, 18 We have shown an increase in MPO in 22 of 24 athletes after a marathon race. MPO is an inflammatory marker, and levels above 350 ng/mL have been shown to predict adverse cardiac events. 22 Of the runners, 58% met or exceeded the clinical threshold defined by the manufacturer, suggesting some cardiac risk could be associated with endurance running. Furthermore, a simultaneous increase in other cardiac markers, including TnT, was observed. All athletes with elevations in the TnT level at or above 0.03 ng/mL and elevated NTproBNP levels had a parallel increase in MPO levels. The average percentage increase in MPO in TnT+ runners was 242.66% compared with 206.37% in TnT-runners, although this difference did not reach statistical significance.
The risk of adverse cardiac events or sudden death after vigorous exercise has been described previously. 3, [5] [6] [7] [8] The incidence of exercise-related deaths is higher in middle-aged men than in younger men and in people who do not exercise regularly. 2, 3, 7 As opposed to younger athletes who are at risk of cardiac events due to congenital abnormalities, adults are at risk for cardiac events due to unknown coronary artery disease. 8 The American Heart Association recommends preparticipation cardiovascular screening (ie, family history of cardiac disease, personal history of cardiac-related symptoms, and physical examination) for athletes of all ages. 37 Although routine use of diagnostic tests such as electrocardiography, echocardiography, and exercise testing is not recommended in younger athletes, these tests may be valuable in men older than 40 years and women older than 50 years who undergo regular physical training and who have risk factors or physical findings suggestive of cardiovascular disease. The marathon runners in this study had a mean age of 49.2 years, classifying them as older athletes. Although the athletes did not report any significant cardiovascular risk factors on the prerace screening inquiry, none of the athletes underwent defined preparticipation cardiovascular screening. MPO levels before and after marathon running may suggest a risk of cardiovascular events and aid in preparticipation screening. Before the race, several runners had MPO levels approaching the 500-pmol/L cut point and the level in 1 runner exceeded the cut point. These athletes may have been at higher risk for cardiac events. In addition, the increase in MPO in conjunction with TnT and NT-proBNP after the race may be more concerning in adult athletes, raising the possibility of "silent" coronary artery disease.
We found a significant elevation in MPO levels following marathon running. Although the elevation in MPO most likely represents a systemic inflammatory response, the concurrent elevation in TnT and NT-proBNP suggests that myocardial injury cannot be excluded. 
